The stock of Edgewise Therapeutics Inc (EWTX) has gone up by 10.01% for the week, with a -6.71% drop in the past month and a 1.42% rise in the past quarter. The volatility ratio for the week is 5.74%, and the volatility levels for the past 30 days are 6.28% for EWTX. The simple moving average for the last 20 days is 1.55% for EWTX stock, with a simple moving average of 58.98% for the last 200 days.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
The 36-month beta value for EWTX is also noteworthy at 0.21. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EWTX is 62.97M, and at present, short sellers hold a 9.15% of that float. The average trading volume of EWTX on April 26, 2024 was 744.33K shares.
EWTX) stock’s latest price update
Edgewise Therapeutics Inc (NASDAQ: EWTX)’s stock price has increased by 5.11 compared to its previous closing price of 15.94. However, the company has seen a 10.01% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-26 that The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Piper Sandler repeating the rating for EWTX by listing it as a “Overweight.” The predicted price for EWTX in the upcoming period, according to Piper Sandler is $48 based on the research report published on March 07, 2024 of the current year 2024.
Goldman gave a rating of “Sell” to EWTX, setting the target price at $5 in the report published on August 25th of the previous year.
EWTX Trading at -0.43% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.02% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 5.74%, as shares sank -7.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.44% lower at present.
During the last 5 trading sessions, EWTX rose by +10.21%, which changed the moving average for the period of 200-days by +124.40% in comparison to the 20-day moving average, which settled at $16.43. In addition, Edgewise Therapeutics Inc saw 53.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from MOORE JOHN R, who sale 8,029 shares at the price of $20.01 back on Feb 09 ’24. After this action, MOORE JOHN R now owns 0 shares of Edgewise Therapeutics Inc, valued at $160,657 using the latest closing price.
Derakhshan Behrad, the Chief Business Officer of Edgewise Therapeutics Inc, sale 4,800 shares at $20.04 during a trade that took place back on Feb 09 ’24, which means that Derakhshan Behrad is holding 7,020 shares at $96,209 based on the most recent closing price.
Stock Fundamentals for EWTX
The total capital return value is set at -0.35. Equity return is now at value -30.10, with -28.33 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -16.98. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 36.81.
Currently, EBITDA for the company is -112.62 million with net debt to EBITDA at 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.50.
Conclusion
In summary, Edgewise Therapeutics Inc (EWTX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
